Mehmet Kos1, Cemil Hocazade2, F Tugba Kos3, Dogan Uncu2, Esra Karakas4, Mutlu Dogan2, Hikmet Gulsen Uncu5, Nuriye Yildirim2, Nurullah Zengin2. 1. Department of Internal Medicine, Faculty of Medicine, Duzce University, Duzce, Turkey. 2. Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey. 3. Department of Medical Oncology, Faculty of Medicine, Duzce University, 81000, Duzce, Turkey. tugbasan@yahoo.com. 4. Department of Internal Medicine, Ankara Numune Education and Research Hospital, Ankara, Turkey. 5. Turkish Drug & Medical Device Institution, Ankara, Turkey.
Abstract
BACKGROUND: It was reported that hematological markers of systemic inflammatory response might be prognostic in various cancer types. We aimed to evaluate the platelet/lymphocyte ratio (PLR) as a prognostic factor and its effect on overall survival in non-small cell lung cancer (NSCLC). METHODS: Clinicopathological characteristics and basal (pretreatment) PLR of 145 patients with NSCLC were evaluated retrospectively. The preoperative or pretreatment blood count data were obtained from the recorded computerized database. PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. RESULTS: A total of 145 patients were enrolled. Median age was 57 years(range 26-83). Receiver operating characteristic curves for overall survival prediction were plotted to verify the optimum cut-off point for PLR. The recommended cut-off values for PLR was 198.2 with a sensitivity of 65.0 % and a specificity of 71.4 %. Median overall survival was 34.0 (95 % confidence interval (CI) 14.7-53.3) months in the group with low PLR (< 198.2), while it was 11.0 (95 % CI 5.6-16.3) months in the group with high PLR (≥ 198.2). The difference between the groups was statistically significant (p < 0.0001). CONCLUSIONS: Our study supports the view that a high basal PLR is a poor prognostic factor in NSCLC. However, the validity of the cut-off values for PLR identified in our study needs further prospective trials.
BACKGROUND: It was reported that hematological markers of systemic inflammatory response might be prognostic in various cancer types. We aimed to evaluate the platelet/lymphocyte ratio (PLR) as a prognostic factor and its effect on overall survival in non-small cell lung cancer (NSCLC). METHODS: Clinicopathological characteristics and basal (pretreatment) PLR of 145 patients with NSCLC were evaluated retrospectively. The preoperative or pretreatment blood count data were obtained from the recorded computerized database. PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. RESULTS: A total of 145 patients were enrolled. Median age was 57 years(range 26-83). Receiver operating characteristic curves for overall survival prediction were plotted to verify the optimum cut-off point for PLR. The recommended cut-off values for PLR was 198.2 with a sensitivity of 65.0 % and a specificity of 71.4 %. Median overall survival was 34.0 (95 % confidence interval (CI) 14.7-53.3) months in the group with low PLR (< 198.2), while it was 11.0 (95 % CI 5.6-16.3) months in the group with high PLR (≥ 198.2). The difference between the groups was statistically significant (p < 0.0001). CONCLUSIONS: Our study supports the view that a high basal PLR is a poor prognostic factor in NSCLC. However, the validity of the cut-off values for PLR identified in our study needs further prospective trials.
Authors: Qing-Qing Li; Zhi-Hao Lu; Li Yang; Ming Lu; Xiao-Tian Zhang; Jian Li; Jun Zhou; Xi-Cheng Wang; Ji-Fang Gong; Jing Gao; Jie Li; Yan Li; Lin Shen Journal: Asian Pac J Cancer Prev Date: 2014
Authors: Karla Sánchez-Lara; Jenny G Turcott; Eva Juárez; Patricia Guevara; Carolina Núñez-Valencia; Luis F Oñate-Ocaña; Diana Flores; Oscar Arrieta Journal: Nutr Cancer Date: 2012-04-10 Impact factor: 2.900